Analysis of the Curative Effect of Cold-Dampness Epidemic Prescription(寒湿疫方)on the Main Symptoms of Quarantined People in Community

Objective:To evaluate the curative effect of"Cold-Dampness Epidemic Prescription(寒湿疫方)"on the main symptoms of quarantined people in community based on real-world research data,and to provide scientific basis for Chinese medicine to fight Coronavirus disease 2019 under the"Wuchang Model".Methods:From February 4,2020 to March 5,2020,the data of community quarantined people who only took"Cold-Dampness Epidemic Prescription(寒湿疫方)"under the management of"Wuchang Model"were collected,and the demographic characteristics,basic diseases,distribution of sick people,treatment process,disappearance time of eight clinical symptoms,adverse reactions and clinical outcomes of patients were statistically analyzed.Results:A total of 951 quarantined people in COVID-19 community were included,including 440 males(46.27%)and 511 females(53.73%),the oldest was 89 years old,the youngest was 2 years old,and the average age was 43.34 years old;Among the quarantined population in the community,there were 141 cases diagnosed by CDC(14.83%),CDC excluded 810 cases(85.17%);106 cases of CDC were diagnosed as COVID-19,accounting for 47.96%of the self-reported cases,and 311 cases(32.70%)had previous medical history;696(73.19%)had no obvious symptoms,and 255(26.81%)developed fever,fatigue,cough,sputum,shortness of breath,loss of appetite,diarrhea and mood,of which 187(19.66%)had cough symptoms,followed by sputum coughing(14.30%)and fever(13.56%).Conclusion:"Cold-Dampness Epidemic Prescription(寒湿疫方)"is effective in treating the clinical symptoms of COVID-19 without obvious adverse reactions.

Traditional Chinese Medicine Diagnosis and Evaluation of the Clinical Effect in Post-hepatitic Cirrhosis based on Fuzzy Analysis

In view of the problem of traditional Chinese medicine (TCM) diagnosis, fuzzy comprehensive evaluation is introduced to the diagnosis and evaluation of the clinical effect of hepatitis. A new diagnosis and evaluation model of the TCM clinical effect standard was presented. The old disputed evaluation model by subjective analysis can be displaced by this objective method in its evaluation system. The foundation of this method is the fuzzy diagnosis model. This method has been realized to diagnose hepatitis and its values in practice has been validated through examples of clinical syndromes of post-hepatitic cirrhosis.

Assessing no-surgical treatment response in bronchogenic carcinoma with contrast material-enhanced computed tomography

Objective:The aim of the study was to evaluate the efficacy of contrast material-enhanced computed tomography(CT) in assessing no-surgical treatment response in bronchogenic carcinoma.Methods:The 67 patients with bronchogenic carcinoma after no-surgical treatment underwent two-phase contrast material-enhanced computed tomography.Two spiral CT scans were obtained at 25 and 90 s respectively after nonionic contrast material was administrated via the antecubital vein at a rate of 4 mL/s by using an autoinjector.Precontrast and postcontrast attenuation values on every scan were recorded and peak height was calculated.Enhancement pattern was evaluated on the image obtained at 25 and 90 s after injection of contrast medium.Results:Precontrast attenuation value,postcontrast attenuation values at 25 and 90 s were(41.26 ± 7.77) Hu,(56.45 ± 10.48) Hu,(70.82 ± 11.99) Hu,respectively.No statistically significant difference in precontrast attenuation was found between our results in this study and the results in our old study(mean precontrast attenuation 40.70 Hu) which was obtained in cases without any therapy(t = 0.593,P = 0.555﹥0.05).Peak height of bronchogenic carcinoma after no-surgical treatment [(29.40 ± 10.73) Hu] were significantly lower than that of bronchogenic carcinoma without any therapy obtained in our old study(mean peak height 35.79 Hu)(t =-4.874,P = 0.001 < 0.05).The 39 among 67 cases appeared homogeneous enhancement at 90 s.At 25 s,there were 26 cases with inhomogeneous enhancement,9 cases with homogeneous enhancement,2 cases with central enhancement,and 2 cases with peripheral enhancement among the 39 cases.Conclusion:Peak heights can reflect the blood supply of bronchogenic carcinoma and might be an index for evaluation of no-surgical treatment response in bronchogenic carcinoma.

Preliminary assessing no-surgical treatment response in bronchogenic carcinoma with three-phase contrast material-enhanced MRI

Objective:The aim of this study was to evaluate the efficacy of three-phase contrast material-enhanced MRI in assessing no-surgical treatment response in peripheral bronchogenic carcinoma preliminarily.Methods:Twenty-two patients with bronchogenic carcinoma after no-surgical treatment underwent three-phase contrast material-enhanced MRI.Three scans were obtained at 25 s,120 s and 180 s respectively after nonionic contrast material was administrated via the antecubital vein at a rate of 2 mL/s by using an autoinjector.Precontrast and postcontrast signal intensity on every scan was recorded.Peak Height(PH) and Maximum Enhancement(Emax) were calculated.Enhancement pattern was evaluated on the images obtained at 120 s and 180 s after injection of contrast medium.Results:Precontrast signal intensity,postcontrast signal intensity at 120 s and 180 s were 478 ± 108,926 ± 209 and 1050 ± 252.PH(571 ± 225) and Emax(119 ± 49) of bronchogenic carcinoma after no-surgical treatment were significantly lower than those of bronchogenic carcinoma without any therapy(mean PH 655,mean Emax 150)(t = 2.178,P = 0.005 < 0.05,t = 4.196,P = 0.001 < 0.05).Six cases among 22 appeared homogeneous enhancement at 180 s.At 120 s,there were 4 cases with inhomogeneous enhancement,1 case with homogeneous enhancement,1 case with peripheral enhancement among the 6 cases.Conclusion:Bronchogenic carcinoma after no-surgical treatment shows a gradual increase to the PH after administration of contrast material.Three-phase contrast material-enhanced MRI can reflect the blood supply of bronchogenic carcinoma and might be effective approach for evaluation of no-surgical treatment response in bronchogenic carcinoma.